Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Atelerix Limited has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are distributed across 2 distinct examiners, ensuring that each application receives an independent review. The workload is also split between 2 distinct art units, which suggests that the company's applications involve different technical aspects of biotechnology. The busiest examiner, VAN BUREN, LAUREN K, is responsible for 1 pending office action.
Since there are 2 pending office actions and 2 distinct examiners, the busiest examiner pending count of 1 confirms that the workload is evenly spread. This distribution across 2 distinct art units means that the company must navigate different sets of art unit policies and examiner behaviors. Practitioners should be prepared for two separate prosecution paths, as the 2 distinct examiners and 2 distinct art units offer no overlap in the current pending workload. The resolution of these 2 pending office actions will be critical for the Biotechnology & Pharmaceuticals portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAN BUREN, LAUREN K | 1 | 40.0% | +58.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037119 | STORING AND/OR TRANSPORTING EXTRACELLULAR NUCLEIC ACIDS | VAN BUREN, LAUREN K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037119 | STORING AND/OR TRANSPORTING EXTRACELLULAR NUCLEIC ACIDS | VAN BUREN, LAUREN K | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18037119 | STORING AND/OR TRANSPORTING EXTRACELLULAR NUCLEIC ACIDS | VAN BUREN, LAUREN K | 1638 | §102§103 | Non-Final OA | — | Pending | May 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAtelerix Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Lauren K Van Buren has the most, with 1 of Atelerix Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
